GSK Divests Non-Core OTCs To Focus On "Priority Brands," Emerging Markets
This article was originally published in The Tan Sheet
GlaxoSmithKline will divest non-core OTC products to accelerate consumer health care growth and help fund a share buy-back program following a financial wipeout in the firm's most recent quarter.
You may also be interested in...
Central and Eastern Europe continue to drive OTC sales growth on the continent, with even low-growth countries matching the best levels in Western Europe.
In a year-and-a-half of heading Prestige Brands Holdings, Matthew Mannelly has been a change agent for the consumer health products firm.
GlaxoSmithKline announces the U.K. launch of Sensodyne Repair & Protect toothpaste as the first consumer oral-care product containing the NovaMin technology GSK acquired in 2009.